References
- Quintás-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond – exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009;6:535–43.
- Nygren P, Sørbye H, Osterlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005;44:203–17.
- Ellis LM, Reardon DA. Is there really a yin and yang to VEGF-targeted therapies? Lancet Oncol 2010;11:809–11.
- Zietman A, Goitein M, Tepper JE. Technology evolution: Is it survival of the fittest? J Clin Oncol 2010;28:4275–9.
- Munshi A, Agarwal JP. Evolution of radiation oncology: Sharp gun, but a blurred target. J Cancer Res Ther 2010;6:3–4.
- Pena PC, Kirova YM, Campana F, Dendale R, Bollet MA, Fournier-Bidoz N, . Anatomical, clinical and radiological delineation of target volumes in breast cancer radiotherapy planning: Individual variability, questions and answers. Br J Radiol 2009;82:595–9.